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Circumferential Margin Involvement Is the Crucial Prognostic
Factor after Multimodality Treatment in Patients with
LocallyAdvanced Rectal Carcinoma
Marleen J.E.M. Gosens,1,4 Rene¤ A. Klaassen,5 Ivonne Tan-Go,3 Harm J.T. Rutten,1Hendrik Martijn,2
Adriaan J.C. van den Brule,3 Grard A.P. Nieuwenhuijzen,1J. Han J.M. van Krieken,4 and Iris D. Nagtegaal4
Abstract Purpose: After preoperative (radio)chemotherapy, histologic determinants for prognostifi-
cation have changed. It is unclear which variables, including assessment of tumor regression,
are the best indicators for local recurrence and survival.
Experimental Design: A series of 201patients with locally advanced rectal cancer (cT3/T4,
M0) presenting with an involved or at least threatened circumferential margin (CRM) on pre-
operative imaging (<2 mm) were evaluated using standard histopathologic variables and four
different histologic regression systems. All patients received neoadjuvant radiochemotherapy
or radiotherapy. The prognostic value of all factors was tested with univariate survival analysis
of time to local recurrence and overall survival.
Results: Local recurrence occurred in only 8% of the patients with a free CRM compared
with 43% in case of CRM involvement (P < 0.0001). None of the four regression systems were
associated with prognosis, not even when corrected for CRM status. However, we did observe
a higher degree of tumor regression after radiochemotherapy compared with radiotherapy
(P < 0.001). Absence of tumor regression was associated with increasing invasion depth and a
positive CRM (P = 0.02 and 0.03, respectively).
Conclusions: Assessment of CRM involvement is the most important pathologic variable
after radiochemotherapy. Although tumor regression increases the chance on a free CRM,
in cases with positive resection margins prognosis is poor irrespective of the degree of therapy-
induced regression.
For patients with locally advanced rectum carcinoma (LARC),
surgery alone is often not curative. In case of cT4 tumors or
a threatened circumferential margin (CRM; <2 mm on
preoperative imaging) in cT3 tumors, long-term neoadjuvant
radio(chemo)therapy is required. This will result in down-
staging and increased local control (1–4). The histopathology
of specimens obtained after this kind of preoperative therapy
is markedly different compared with untreated cases. Various
stages of histologic tumor regression may be present, often
resulting in changed morphology.
Histologic changes after the radiochemotherapy regimen
range from absence of any treatment effect to a complete re-
sponse with no residual tumor identified. One of the first sys-
tems for grading histologic regression focused on patients with
esophageal carcinoma who were treated with radiochemother-
apy (5). Their results showed that, after multivariate analysis,
only grading of tumor regression was a significant predictor for
disease-free survival (5). Subsequently, this system was modified
by Dworak et al. (6) for grading regression in the rectum.
Currently, several different methodologies for measuring the
degree of histologic tumor regression after radiochemotherapy in
rectal cancer have been described (6–10) but none has become
universally accepted. Reproducibility seems to be a key factor.
The objective of our study is to evaluate which factors deter-
mine outcome in patients with LARC after radiochemotherapy,
focusing on the contribution of histologic tumor regression
grading and the CRM. Tumor regression after radiochemother-
apy was measured using four different methodologies and
evaluated for prognostic effect with respect to overall survival
and local recurrence. CRM was evaluated according to Quirke
et al. (11, 12). Additionally, prognostic implications of
clinicopathologic and histologic variables were determined.
Materials andMethods
Patient selection. The patient population consisted of a consecutive
series of patients with LARC with biopsy-proven adenocarcinoma. All
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patients received multimodality treatment at the Catharina hospital
between 1994 and 2005 (13). Patients were referred from all over the
Netherlands based on the assumption of the referring surgeon that a
free CRM was unlikely to be obtained without neoadjuvant treatment.
Until August 2005, 201 patients with stage cT4 or cT3 and a predicted
CRM of <2 mm have been treated. Confirmation of the tumor proximity
to the CRM and the absence of distant metastasis (M0) on magnetic
resonance imaging were crucial for enrollment. Median follow-up was
22.8 months (range, 0-124 months). Approval for the study was given
by the local ethical committee of the Catharina hospital.
Therapy. Preoperatively, patients received different treatment regi-
mens, considered state of the art at the time of treatment. Long-term
radiotherapy (n = 74) involved a total dose of 50.4 Gy in 1.8 Gy
fractions, five times a week. Two radiochemotherapy schedules have
been used. The MAYO schedule, hereafter mentioned as interrupted
schedule (n = 102), comprises concurrent radiotherapy and chemo-
therapy: a total irradiation dose of 50.4 Gy, 1.8 Gy per fraction during
5 weeks synchronously with 5-fluorouracil (350 mg/m2) and leuco-
vorin (20 mg/m2) in irradiation weeks 1 and 5. The radiation scheme of
the continuous radiochemotherapy regimen (n = 25) compromises
45 Gy in fractions of 1.8 Gy during 5 weeks. On every radiation day,
820 mg/m2 capecitabine was administered twice and 50 mg/m2 oxa-
liplatin was given at the first irradiation day of each week.
Surgery. The objective in both cT3 and cT4 tumors was to obtain a
radical resection (negative CRM). Especially in cT4 tumors, the CRM
encompassed surrounding structures (i.e., prostate vesicle, vaginal wall,
pelvic floor, uterus, and sacrum). The CRM was considered negative if
the outer margin of the en bloc specimen was negative.
In case of all treatment schedules, surgery was done 6 to 8 weeks
after the last radiation date. All patients underwent resection by
experienced and designated colorectal surgeons (H.J.T. Rutten and
G.A.P. Nieuwenhuijzen) who routinely do total mesorectal excision
surgery. The extended surgical procedures used were abdominoperineal
resection (n = 98), low anterior resection (n = 91), abdominotranssacral
resection (n = 9), and exenteration (n = 3). The total mesorectal excision
principle was adhered to in all cases, even in extended resections (14).
Histopathologic assessment. Surgical specimens were assessed
according to the protocol of Quirke et al. (11, 12). The most important
issue is assessment of the CRM. To determine the CRM, the lateral
resection margin of the fresh specimen was inked and subsequently the
specimen was fixed in formalin for 48 h. Blocks of the tumor in relation
to the inked CRMwere collected. Measurements of themargin were done
microscopically. A specimen with tumor V1 mm from the inked margin
was considered as having a positive CRM. Classification of tumors was
done using the WHO guidelines; a tumor was considered mucinous
when the proportion of the mucinous component was z50%. Tumors
were graded according to histologic differentiation into well, moderately,
and poorly differentiated based on the poorest differentiated part of the
tumor excluding the invasive front (15). Growth patterns were assessed as
circumscribed or infiltrating (16). Evaluation of the tumor biopsies
included assessment of tumor type and differentiation grade.
Histologic regression grading. Histologic therapy-induced tumor
regression was assessed according to four different grading systems
described by Dworak et al. (6), Scott et al. (7), Bouzourene et al. (8)
and Ro¨del et al. (9). All four regression systems semiquantitatively asses
the relative proportion of residual tumor to stromal fibrosis. The
following descriptions characterized the different regression grades of
the regression systems used: Dworak grade 0: no regression detect-
able, grade 1: dominant tumor mass with obvious fibrosis and/or
vasculopathy, grade 2: dominantly fibrotic changes with few tumor
cells or groups (easy to find), grade 3: very few (difficult to find
microscopically) tumor cells in fibrotic tissue with or without mucin,
and grade 4: no tumor cells, only fibrotic mass or mucin; Scott
minimal: less than 1/3 tumor regression, moderate: 1/3 to 2/3 tumor
regression, good: more than 2/3 regression, and maximal: no primary
tumor remaining; Bouzourene tumor regression grade (TRG) 5: tumor
shows no signs of regression, TRG 4: residual tumor cells outgrowing
the fibrosis, TRG 3: more tumor cells than TRG 2 but fibrosis still
predominates, TRG 2: rare residual cancer cells scattered throughout
the fibrosis, and TRG 1: absence of residual cancer and fibrosis extend-
ing through the different layers of the rectal wall; and Ro¨del 0: no
regression or <25% of tumor mass, Ro¨del 1: 25% to >50% tumor
regression, and Ro¨del 2: complete regression.
When no tumor could be found macroscopically, sufficient tumor
blocks were sampled to establish a complete response. In the present
series, 21 patients had a complete response. The mean number of block
Fig. 1. Representative slides stained
with H&E of different degrees of
tumor regression observed after
radio(chemo)therapy in patients with
LARC. A, no sign of regressive changes,
the fibrosis present is probably intrinsic to
tumor development. Original magnification,
50. B, marked fibrosis but large masses of
vital tumor can still be observed. Original
magnification, 50. C, predominately
fibrotic changes with smaller tumor masses.
Original magnification, 50. D, extensive
tumor regression with few small clusters of
tumor cells (arrow) scattered through the
fibrotic area. Original magnification, 50.
The boxed area in D is depicted with a
higher magnification as an insertion in this
panel. Three small clusters of tumor cells
can be appreciated. Original magnification,
400.
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samples collected from the fibrotic area was 9 (median, 7; range, 3-22).
Figure 1 shows representative examples of different degrees of tumor
regression. These microscopic images were digitalized using a Zeiss
Axioskop 2 Plus microscope with a Sony 950P camera attached to it.
Images were digitized using 5 or 40 Plan-Neofluar objectives (Carl
Zeiss MicroImaging). A cellular mucin was considered as absence of
residual tumor. The degree of tumor regression was determined
semiquantitatively by two pathologists (J.H.J.M. van Krieken and I.
Tan-Go) who were blinded for patients’ clinical outcome. In addition,
the amount of necrosis and the presence of calcifications were scored
as alternative variables for regression.
Statistical analysis. Data were analyzed with the Statistical Package
for the Social Sciences package (Statistical Product and Service Solutions
11.0 for Windows, SPSS, Inc.). Univariate survival analyses of time to
death were done using the Kaplan-Meier method with the time of
surgery as the entry date. Differences in observed survival between
groups were tested for statistical significance using log-rank tests. m2
tests were used to determine correlations between categorized variables.
Multivariate analysis was done using the Cox proportional hazards
regression model [backward elimination (conditional)]. P values of
V0.05 were considered as statistically significant.
Results
Pretreatment patient characteristics. The majority of the
patients were male (61%); median age was 63 years (range,
35-86 years). Clinical T stage was cT4 in 59% and cT3 in 41% of
the patients. Slightly more CRM involvement was present in
cT4 tumors (25% versus 17%; P = 0.13). There was no
difference in outcome between cT3 and cT4 tumors (local
recurrence, 12% versus 19%, P = 0.31; metastases, 22% versus
29%, P = 0.50; overall 5-year survival, 58% versus 47%, P =
0.22). Because there was no significant difference in outcome,
we combine both groups for further analysis.
Correlations between pretreatment factors and regres-
sion. The three-tier Ro¨del system was used to show correla-
tions between the degree of regression and pretreatment and
posttreatment factors (Table 1). The Ro¨del system consists of
the lowest amount of categories and therefore avoids sub-
groups containing small numbers of patients. Furthermore, this
system showed significant correlation within the framework
of a randomized trial (9).
A strong association between treatment regimen and tumor
regression was found (Table 1). The degree of tumor regres-
sion was significantly higher after radiochemotherapy (12%
Ro¨del 2) compared with radiotherapy (8% Ro¨del 2; P < 0.001).
Regression was more pronounced in tumors showing
poor differentiation in their pretreatment biopsy (P = 0.03).
Tumor regression was not influenced by preoperative cT
stage.
Table 1. Correlations between tumor regression and pretreatment and posttreatment factors
Factor type Factor Category Ro¨del 0,
n (%)
Ro¨del 1,
n (%)
Ro¨del 2,
n (%)
P
Pretreatment Clinicopathologic Therapy Radiotherapy 53 (72) 15 (20) 6 (8) <0.001
Radiochemotherapy 48 (38) 64 (50) 15 (12)
Clinical T stage cT3 38 (46) 32 (38) 13 (16) 0.12
cT4 63 (53) 47 (40) 8 (7)
Differentiation grade Good/moderate 56 (58) 31 (32) 10 (10) 0.03
Poor/undifferentiated 20 (36) 29 (52) 7 (12)
Posttreatment* ypT stage ypT1, T2 5 (29) 12 (71) 0.02
ypT3, T4 96 (59) 66 (41)
ypN stage ypN0 65 (50) 49 (37) 17 (13) 0.38
ypN1 24 (51) 19 (40) 4 (9)
ypN2 12 (52) 11 (48) 0 (0)
ypTNM Stage I 5 (36) 9 (64) 0.16
Stage II 51 (62) 31 (38)
Stage III 36 (55) 30 (45)
CRM Negative 71 (52) 66 (48) 0.03
Positive 30 (70) 13 (30)
Histologic Type Adenocarcinoma 75 (55) 62 (45) 0.50
Mucinous 19 (53) 17 (47)
Differentiation grade Good/moderate 62 (56) 49 (44) 0.40
Poor/undifferentiated 39 (59) 27 (41)
Growth pattern Circumscript 17 (68) 8 (32) 0.20
Diffuse 83 (56) 64 (44)
Lymphoid reaction None/few 56 (55) 45 (45) 0.20
Moderate 32 (57) 24 (43)
Extensive 12 (80) 3 (20)
Eosinophilic infiltrate None 71 (55) 57 (44) 0.19
Moderate/extensive 29 (64) 16 (36)
Lymphangio invasion No 94 (58) 69 (42) 0.54
Yes 6 (54) 5 (45)
Calcification No 76 (60) 50 (40) 0.18
Yes 25 (51) 24 (49)
Tumor necrosis No 24 (32) 52 (68) <0.001
Yes 76 (78) 22 (22)
Abbreviations: ypT, pathologic T stage; ypN, pathologic N stage; ypTNM, pathologic tumor stage.
*After a complete response (Ro¨del 2), posttreatment factors could not be assessed.
Value of CRMAssessment after Radiochemotherapy
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Posttreatment clinicopathologic and histologic factors and
prognosis. CRM involvement, lymph node status, and tumor
stage were strongly associated with both local recurrence and
overall survival (Table 2). CRM involvement was the strongest
predictor of local recurrence (43% versus 8%, at 24 months;
P < 0.001) and overall survival (58% versus 80%; P = 0.004;
Fig. 2).
Local recurrence rates increased and overall survival rates
decreased with the number of lymph nodes involved (P =
0.001). Mucinous histology and poor differentiation were both
associated with poor prognosis. Although lymphangio invasion
was not associated with local recurrence, it did predict poor
overall survival (40% versus 75%; P = 0.04). All the analyses
were repeated for the different treatment regimens, but this did
not reveal different results. However, the groups are too small
for firm conclusions per regimen.
Multivariate analysis of clinicopathologic factors. Because
histologic factors could not be determined in patients with a
complete response, multivariate analysis for local recurrence
and overall survival was done for clinicopathologic factors
(category pathologic T stage, pathologic N stage, and CRM)
and the Ro¨del system only. A hazard ratio (HR) of 1 was
attributed to the most favorable category. In case of local
recurrence, the CRM was the only factor significantly associated
with this event (HR, 4.44; 95% confidence interval, 1.83-10.81;
P = 0.001). With respect to overall survival, both N status and
CRM were selected by the Cox regression model using
conditional backward elimination: pathologic N stage I: HR,
1.75, 95% confidence interval, 1.01-3.05, P = 0.046; pathologic
N stage II: HR, 2.60, 95% confidence interval, 1.28-5.27,
P = 0.008; and CRM: HR, 1.68, 95% confidence interval, 0.99-
2.85, P = 0.054.
Correlations between posttreatment factors and regression. His-
tologic posttreatment factors could only be correlated to Ro¨del
0 and 1 because no tumor cells were left after complete tumor
regression (Ro¨del 2). However, after complete tumor regres-
sion at the site of the primary tumor, positive lymph nodes were
still found in 4 (19%) of 21 complete responders (Table 1). In
two cases, no lymph nodes were found. More extensive
histologic tumor regression was present in ypT1 and ypT2
tumors as could be expected. As a consequence, an involved
CRM was observed more than twice as often in patients with
limited regression (Ro¨del 0) compared with patients with
Ro¨del 1 (70% versus 30%; P = 0.03). No significant correlations
were found between regression and histologic posttreatment
factors. Tumor necrosis, which might be considered as an
alternative variable for regression, was inversely related to the
degree of regression. In 78% of the tumors with minimal (<25%
of the tumor mass) or no regressive changes, necrotic areas were
observed. After more extensive regression, these areas were
identified in only 22 (22%) of tumor specimens.
Regression grading and prognosis. Surprisingly, none of the
regression systems analyzed were found to be significantly
associated with local recurrence. In addition, no correlation
with overall survival was found (Table 3). We repeated the
analysis correcting for CRM status because this factor was found
Table 2. Univariate analysis of posttreatment pathologic variables in relation to local recurrence and overall
survival
Factor type Factor Category n (%) % LR at 24 mo P % alive at 24 mo P
Clinicopathologic ypT stage ypT0-ypT2 38 (19) 3 0.061 89 0.04
ypT3, ypT4 162 (81) 19 72
ypN stage ypN0 131 (65) 9 0.001 81 0.001
ypN1 47 (23) 25 69
ypN2 23 (12) 46 40
ypTNM No residual tumor 14 (7) 0 0.022 100 0.004
Stage I 19 (9) 0 81
Stage II 97 (49) 13 82
Stage III 70 (35) 29 59
CRM Negative 158 (79) 8 <0.001 80 0.004
Positive 43 (21) 43 58
Histologic Type Adenocarcinoma 137 (79) 13 0.04 75 0.02
Mucinous 37 (21) 32 60
Differentiation grade Good/moderate 111 (63) 12 0.04 80 0.05
Poor 66 (37) 26 61
Growth pattern Circumscript 25 (14) 17 0.90 59 0.35
Diffuse 147 (86) 18 76
Lymphoid reaction None/few 101 (58) 22 0.23 67 0.19
Moderate 56 (32) 15 75
Extensive 16 (9) 8 94
Eosinophilic infiltrate None 129 (74) 19 0.85 73 0.33
Moderate/extensive 45 (26) 17 77
Lymphangio invasion No 163 (94) 16 0.51 75 0.04
Yes 11 (6) 30 40
Calcification No 126 (71) 19 0.58 75 0.56
Yes 51 (29) 13 67
Tumor necrosis No 76 (43) 6 0.02 68 0.76
Yes 99 (57) 22 75
NOTE: Patients with missing data were excluded from local recurrence and overall survival analysis.
Abbreviation: LR, local recurrence.
Imaging, Diagnosis, Prognosis
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the most potent predictor of prognosis. In the CRM-negative
cases (n = 158), again grading of tumor regression lacked
prognostic implications for local recurrence and overall
survival.
Reproducibility of regression grading. To test reproducibility
of our results and to determine the interobserver variability,
tumor regression was also assessed by a second pathologist in
all cases (n = 201). Analysis with the data obtained by the
second pathologist confirmed our initial finding (data not
shown). To express interobserver variability, measurements of
agreement were indicated in j values for each system
(Supplementary Data). j values for the regression system as a
whole and for two successive categories within a system were
calculated. Categories defining minimal regressive changes are
more difficult to discriminate from one another (j values
ranging from 0.29 to 0.47) than categories defining extensive to
complete regression (j values ranging from 0.77 to 0.85). All
four systems showed that that j values improve as the amount
of residual tumor decreases.
Discussion
Our study shows the great importance of optimal surgery for
patients with LARC who are treated with radiochemother-
apy. Although it has been suggested that neoadjuvant therapy
could compensate for poor surgery, we show that radical
excision (free CRMs) is essential for local control (Fig. 2). The
prognostic value of standard clinicopathologic factors, such
as CRM, lymph node status, and tumor stage, is superior to
grading therapy-induced tumor regression in patients with
LARC (Table 1). This finding was also confirmed in a mul-
tivariate model. CRM involvement is a very important risk
factor for local recurrence that is vastly influenced by treatment
factors (neoadjuvant therapy and surgery). Evaluation of the
CRM could therefore be considered as an early alternative end
point for future randomized trials comparing different treat-
ment regiments for patients with LARC (17). The most
advantageous treatment strategy for this specific subset of
patients requires a multidisciplinary approach. This implies
not only high-quality surgery and neoadjuvant therapy but
also optimal imaging to identify patients who will benefit from
this strategy and accurate pathologic assessment of CRM in-
volvement (11, 12) for evaluating successfulness of the strategy.
The degree of tumor regression was found to be correlated
with the neoadjuvant treatment regimen used. Tumor regres-
sion was found to be more extensive after radiochemotherapy
compared with long-term radiotherapy, which is in accordance
with literature (18, 19). We were not able to show any prog-
nostic effect of regression scoring, irrespective of stratification
for CRM involvement. However, tumor regression is important
because the chance to obtain a negative CRM is increased after
extensive tumor regression (Table 1).
The percentage of patients with a positive margin (21%) was
relatively low taking into account that the inclusion criterion
was a threatened CRM. This finding agrees with reports by
Mawdsley et al. (17) and Glynne-Jones et al. (20) who found
that 20% of the patients with LARC had a positive CRM after
radiochemotherapy. LARC was defined by these authors as
borderline resectable or irresectable disease; patients underwent
curative surgery after neoadjuvant chemoradiation. Univariate
analyses done in the present study confirmed the importance of
the CRM for both overall survival (P = 0.004) and local
recurrence (P < 0.001). Multivariate analysis of clinicopatho-
logic factors confirmed the importance of CRM involvement
for the prediction of local recurrence (HR, 4.44; 95%
confidence interval, 1.83-10.81; P = 0.001). Several other
studies report similar results about the importance of the
CRM as a predictor for outcome after neoadjuvant treatment
(17, 21–24).
Numerous studies investigated the prognostic value of tumor
response after neoadjuvant therapy in rectal cancer, without
consistent results. Similar to our study, no correlation was
found in three different studies (19, 25, 26) with a total
number of 385 patients. On the other hand, tumor regression
was associated with local recurrence (389 patients; refs. 4, 8, 27,
28), overall survival (247 patients; refs. 8, 29), or disease-free
survival (270 patients; refs. 4, 8, 9, 29).
However, reproducibility of tumor regression assessment
leaves room for improvement (Supplementary Data). Measure-
ments on the variance between two successive categories within
each system showed that j values improve as the amount of
Fig. 2. Kaplan Meier curves of CRMinvolvement in relation to local recurrence (A)
and overall survival (B). Black lines, patients with an involved margin; gray lines,
patients with a free CRM.
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residual tumor decreases. Distinguishing absence (Fig. 1A)
from little regressive signs (Fig. 1B) was reproduced poorly,
probably because formation of fibrosis is also an intrinsic
characteristic of tumor development. Discriminating intrinsic
tumor fibrosis from therapy-induced fibrosis based on mor-
phology is difficult. A complete tumor response, on the other
hand, which is the only clearly definable degree of tumor
regression, largely depends on tissue processing and sampling,
which are often responsible for discrepancies in literature about
the rate of complete responders (9, 29). A possible way to
standardize the criteria for a complete response could be as
follows: sample five sites of the tumor area, and if no tumor is
present in these blocks, the whole area suggestive for disease
should be embedded in paraffin blocks. If still no tumor is
present, H&E slides will be obtained from each block at three
levels. If no tumor was found after this procedure, a complete
response was established (30). The lack of clear definitions with
respect to the morphologic aspects of therapy-induced fibrosis
and a complete tumor response explains both interobserver and
interstudy variance.
The term locally advanced is also not clearly defined.
Definitions range from patients who received long-term neo-
adjuvant radiotherapy or radiochemotherapy to patients with
positive lymph nodes, advanced cT3 or cT4, or patients with a
threatened CRM. Three of the nine studies investigating the
prognostic value of grading tumor regression stated to have
analyzed patients with LARC (8, 25, 28). The percentages of
stage cT4 in these three reports range from 12% (25) to 32%
(28) and are relatively low compared with the percentage of cT4
in the present population (59%). Moreover, none of the reports
on LARC selected patients based on a threatened CRM (a
predicted CRM on magnetic resonance imaging of <2 mm).
These unique pretreatment characteristics distinguish the
present population from other reports about patients with
LARC. These differences in patient selection can also explain
the inconsistency, about the prognostic implications of tumor
regression, between the findings described in the present study
and those described by others.
Our data indicate that tumor response to neoadjuvant long-
term radiotherapy or radiochemotherapy results in tumor
shrinkage (Fig. 3, arrow) rather than fragmentation of the
tumor (Fig. 3, dotted arrow). The scenario of tumor fragmen-
tation implicates that the degree of tumor regression is not
informative for depth of infiltration (e.g., vital tumor cells may
still be scattered throughout the whole fibrotic area and reach
Table 3. Univariate analysis of regression systems in relation to local recurrence and overall survival
System Total population (N = 201) CRM-negative patients only (n = 158)
n (%) % LR at 24 mo P % alive at 24 mo P n (%) % LR at 24 mo P % alive at 24 mo P
Dworak
Grade 0 18 (9) 30 0.21 59 0.13 13 (8) 10 0.61 74 0.31
Grade 1 83 (41) 18 75 59 (38) 7 85
Grade 2 57 (28) 19 70 48 (30) 12 66
Grade 3 22 (11) 0 75 17 (11) 0 78
Grade 4 21 (11) 5 94 21 (13) 5 94
Scott
Minimal 48 (42) 19 0.26 68 0.29 59 (37) 10 0.11 79 0.15
Moderate 35 (18) 17 73 27 (17) 13 74
Good 61 (30) 9 76 51 (33) 0 77
Maximal 21 (10) 5 94 21 (13) 5 94
Bouzourene
TRG 5 17 (9) 31 0.19 57 0.29 12 (8) 11 0.53 72 0.66
TRG 4 82 (41) 18 72 58 (36) 7 81
TRG 3 58 (29) 19 77 47 (30) 13 76
TRG 2 23 (11) 0 66 20 (13) 0 69
TRG 1 21 (10) 5 94 21 (13) 5 94
Ro¨del
0 101 (50) 20 0.44 74 0.15 71 (45) 8 0.95 86 0.15
1 79 (39) 14 69 66 (42) 9 68
2 20 (11) 5 94 21 (13) 5 94
Fig. 3. Schematic representation of the relation between the degrees of tumor
regression and CRM involvement. Black, areas with vital tumor cells; gray, fibrotic
areas.A, pretreatment situation: the tumor is locally advanced (cT4) and the CRMis
threatened.The contours of this pretreatment stage are also depicted in B, C, andD.
B andD, after neoadjuvant long-course radiotherapy or radiochemotherapy, two
different scenarios about tumor regression are sketched. B, ‘‘tumor shrinkage’’
scenario in which the infiltration depth is less extensive than in the pretreatment
situation. D, ‘‘tumor fragmentation’’ scenario that implies scattered tumor cells
throughout the whole fibrotic area, reaching the initial infiltration depth. However,
if the CRM is still positive after tumor shrinkage (C), patient’s outcome will still be
poor irrespective of the degree of tumor regression.
Imaging, Diagnosis, Prognosis
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the pretreatment level of tumor invasion). Tumor fragmentation
after neoadjuvant treatment still results in CRM involvement.
However, our data suggest that tumor shrinkage is the main
event after neoadjuvant therapy, resulting in negative CRM,
which was obtained in f80% of patients with a clinically
threatened margin. Moreover, our data revealed that patients
with a negative CRM experienced significantly less local recur-
rence compared with patients with a positive CRM. This indicates
that the fibrotic area that is depicted in gray in Fig. 3B is sterile,
pleading for the scenario of tumor shrinkage. However, if the
CRM is involved, patient prognosis remains poor despite elabo-
rate histologic regression after neoadjuvant treatment (Fig. 3C).
In case of overall survival, lymph node status revealed to have
strong prognostic implications. Because treatment of patients
with LARC consists of intensified local treatment aimed on the
primary tumor, locoregional tumor spread resulting in positive
lymph nodes (and as a consequence of decreased overall sur-
vival) is essentially not affected by this treatment. This was
illustrated by our finding that positive lymph nodes can still be
found after complete regression of the primary tumor mass
(Table 1), which can explain why these patients can still
develop metastasis.
In this study, which investigates a unique population of
patients with LARC that had a threatened CRM and a high
percentage of cT4, we have shown that assessment of the CRM
is the most important pathologic factor after radiochemother-
apy. Extensive tumor regression, resulting in tumor shrinkage,
is essential for obtaining a free CRM, but incomplete resection
implies a poor prognosis irrespective of the degree of these
regressive changes.
Value of CRMAssessment after Radiochemotherapy
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